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Available online 17 April 2015Wehere describe a multimodality neuroimaging containing data from healthy volunteers and patients, acquired
within the Lundbeck Foundation Center for Integrated Molecular Brain Imaging (Cimbi) in Copenhagen,
Denmark. The data is of particular relevance for neurobiological research questions related to the serotonergic
transmitter system with its normative data on the serotonergic subtype receptors 5-HT1A, 5-HT1B, 5-HT2A, and
5-HT4 and the 5-HT transporter (5-HTT), but can easily serve other purposes.
The Cimbi database and Cimbi biobankwere formally established in 2008with the purpose to store thewealth of
Cimbi-acquired data in a highly structured and standardized manner in accordance with the regulations issued
by the Danish Data Protection Agency as well as to provide a quality-controlled resource for future hypothesis-
generating and hypothesis-driven studies.
The Cimbi database currently comprises a total of 1100 PET and 1000 structural and functional MRI scans and it
holds amultitude of additional data, such as genetic and biochemical data, and scores from17 self-reported ques-
tionnaires and from 11 neuropsychological paper/computer tests. The database associated Cimbi biobank cur-
rently contains blood and in some instances saliva samples from about 500 healthy volunteers and 300
patientswith e.g.,major depression, dementia, substance abuse, obesity, and impulsive aggression. Data continue
to be added to the Cimbi database and biobank.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
For more than a decade, the Neurobiology Research Unit in Co-
penhagen, Denmark, has together with its partners in the LundbeckUnit, Rigshospitalet, N6931, 9
. This is an open access article underFoundation Center for Integrated Molecular Brain Imaging (Cimbi,
http://www.cimbi.org) systematically collected high-resolution mo-
lecular, functional and structural brain imaging data and relevant as-
sociated data from several hundreds of healthy individuals and
patients with various neuropsychiatric disorders with the aim of
uncovering basic questions regarding interindividual differences in
behavior and personality. The overall research framework in Cimbi
is shown in Fig. 1.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Diagram illustrating the overall picture of Cimbi activities with the main research areas. The original main focus of Cimbi was on the healthy individual, but research has been put
into context by extending the view to include various diseases.
1214 G.M. Knudsen et al. / NeuroImage 124 (2016) 1213–1219We have been particularly interested in how individual differences
in healthy volunteersmay serve as important predictors of vulnerability
to neuropsychiatric disorders, including personality traits (da
Cunha-Bang et al., 2013; Frokjaer et al., 2008; Kalbitzer et al., 2009), af-
fective disorders (Baare et al., 2010; Frokjaer et al., 2009, Frokjaer et al.,
2010b;Macoveanu et al., 2014;Madsen et al., 2014) andmemory disor-
ders (Haahr et al., 2013;Madsen et al., 2011c; Madsen et al., 2011a).We
have primarily chosen to investigate healthy volunteers in order to ex-
clude confounds such asmedication bias and scar effects from prior dis-
ease processes and to separate trait and state factors. Occasionally, the
volunteers have been selected based on their genotype or on a familial
predisposition to, e.g., depression. Detailed family history and severe
stressful life events have been recorded and strict exclusion criteria
have been applied (Table 1). In some studies, we have included patients
with different neurological and psychiatric disorders. These include
studies in Alzheimer's Disease (Hasselbalch et al., 2008; Madsen et al.,
2011c; Marner et al., 2011, Marner et al., 2012), depression (Madsen
et al., 2012a), substance abuse (Erritzoe et al., 2011), obesity (Erritzoe
et al., 2009; Erritzoe et al., 2010a; Haahr et al., 2015), aggression, schizo-
phrenia (Erritzoe et al., 2008; Rasmussen et al., 2010, Rasmussen et al.,
2011) and epilepsy.
Cimbi studies particularly address the brain serotonergic (5-HT)
transmitter system because of its involvement in a wide range ofTable 1
General exclusion criteria for healthy volunteers in Cimbi.
• Family history of neurological or primary psychiatric disorders (DSM IV Axis I or
WHO ICD-10 diagnostic classiﬁcations)
• Psychopharmacological treatment (present and prior). Current use of any
medications affecting the brain or cerebral blood ﬂow
• Anemia or drug treated diabetes
• Malfunction of the liver, kidney, immune system or thyroid gland, including
systemic corticosteroid treatment
• Ongoing pregnancy or breast feeding
• Chemotherapy
• Lifetime drug use of more than 50 times cannabis or more than 10 times of any
other drug
• Ongoing alcohol consumption above the recommendations from the National
Board of Health, i.e. 7 and 14 units/week for women and men, respectively, or
ongoing treatment of alcohol abuse (antabus)
• Lack of ﬂuency in Danish
• History of learning disability
• Impairment of vision or hearing
• Claustrophobia
• Irremovable metallic or electronic implants, e.g. a pace maker or bracespsychophysiological functions, including feeding, mood, sleep, aggres-
sion, pain and in the generation and regulation of emotional behavior
(Olivier, 2015). Serotonin is also an important neurotransmitter in
brain development and it helps to overcome challenges from the ever-
changing environments. Furthermore, it interacts with genetically
determined individual differences in personality that critically shape
complex human behavior and social interplay. We have by means of
high-resolution Positron Emission Tomography (PET) and Magnetic
Resonance Imaging (MRI) imaged the 5-HT neurotransmitter system
in humans with the currently available PET-radiotracers (Fig. 2) and
established normative data for the 5-HTT (Erritzoe et al., 2010b), the
5-HT2A (Adams et al., 2004) and the 5-HT4 (Madsen et al., 2011b) recep-
tors. A novel agonist radioligand for 5-HT2A receptor PET studies,
[11C]Cimbi-36, has also been developed and validated in humans
(Ettrup et al., 2014) and 5-HT4 receptor binding has been shown to be
inversely related to 5-HT brain levels (Fisher et al., 2012; Haahr et al.,
2014).
Functional MRI (fMRI) in conjunction with various pharmacological
challenges of the 5-HT system has been obtained with emotional faces
task (Grady et al., 2013; Hornboll et al., 2013) or a gambling task
(Macoveanu et al., 2013b, Macoveanu et al., 2013c; Macoveanu et al.,
2013a). fMRI has also been investigated in relation to genotype (Fisher
et al., 2012) and bright light intervention (Fisher et al., 2014). Diffusion
tensor imagingdata has also been related to personality traits associated
with depression (Madsen et al., 2012c).
We have collected also awide range of associated data, including de-
mographic, somatic, neurological and neuropsychological data, based
on self-reported questionnaires as well as semi-structured interviews,
tests and assessments. These data have so far mostly been used in con-
junction with imaging data, e.g., da Cunha-Bang et al. (2013), Frokjaer
et al. (2010b), and Haahr et al. (2013) but have also served as a basis
for analyses in their own right (Stenbæk et al., 2014a, 2014b, 2015).
Furthermore, we have systematically collected and stored saliva-
and blood (plasma, serum, whole blood, buffy coat) samples, enabling
future determination of relevant associated biological, biochemical
and genetic variables. Apart from standard screening blood tests, there
are for some cohorts biochemical measures of serum brain derived neu-
rotrophic factor (BDNF) (Klein et al., 2010; Trajkovska et al., 2007;
Trajkovska et al., 2008), amino acids (Macoveanu et al., 2013a), and
sex steroid hormones (Frokjaer et al., 2010a). In a large proportion of
the Cimbi cohort saliva samples have been acquired overnight for deter-
mination of cortisol awakening response (Frokjaer et al., 2013; Frokjaer
et al., 2014; Madsen et al., 2012c; Madsen et al., 2012b; Nalla et al.,
Fig. 2. Coregistered structural MRI and PET brain images of (from top row and down) the
5-HT1A, 5-HT1B, 5-HT2A, and 5-HT4 receptors and the 5-HT transporter (5-HTT), respec-
tively. Each image represents an average of 5 scans. The color bar shows the non-displace-
able binding potentials (BPND). Courtesy of Vincent Beliveau, Cimbi.
Table 2
Overview of the patient/case cohorts in Cimbi.
Patient/case category (Fig. 1) Number of subjects
(females/males,
age range)
• Dementia
○Mild Cognitive Impairment (MCI) 11 (5/6, 62–92)
○ Alzheimer's Disease 13 (4/9, 69–90)
• Depression
○ Familial predisposition to major depression 34 (21/13, 27–82)
○ Seasonal Affective Disorder 76 (52/24, 22–47)
• Substance abuse
○MDMA and/or hallucinogens 25 (3/22, 28–43)
○ Other stimulants, including alcohol and tobacco 56 (27/29, 23–58)
• Obesity 55 (43/12, 28–70)
• Aggression 40 (0/40, 20–62)
• Epilepsy 32 (17/15, 20–61)
• Schizophrenia 35 (8/27, 27–47)
1215G.M. Knudsen et al. / NeuroImage 124 (2016) 1213–12192015). In many cases, DNA has been puriﬁed and is also stored as such.
Some genetic polymorphisms, e.g., (Kalbitzer et al., 2010; Klein et al.,
2010) have been determined and are stored in the database. With
many new instruments being added over the years and fewer being
discarded, the Cimbi investigational programme has been a standard-
ized but growing entity.
With the purpose of storing the wealth of Cimbi-acquired data in a
highly structured manner in accordance with the regulations issued
by the Danish Data Protection Agency as well as to provide a quality-
controlled resource for future hypothesis-generating and hypothesis-
driven studies, we formally established the Cimbi database and Cimbi
biobank in 2008. Containingdata acquired since 2000, this database con-
stitutes a most comprehensive and unique repository of the serotonin
system in well-characterized human individuals.
Cohort overview
As of January 1st, 2015, the Cimbi Database contains data frommore
than 1600 healthy subjects and 375 patients with neuropsychiatric dis-
orders, with an age range of 17–93 years (mean age= 39.0± 14.1) and
both genders (59% females). All subjects are Danish citizens and morethan 97% are Caucasians. For a subgroup (n = 657) vocational educa-
tional scores are available and range from 1 to 5 (mean = 3.5 ± 1.5),
rated on a 5-point Likert scale from1 (no vocational education) to 5 (ac-
ademic education N 4 years). Subjects have been enrolled throughmore
than 50 different research projects, some of which are still ongoing. All
studies have been approved by the local scientiﬁc ethics committee and
the Danish Data Protection Agency prior to initiation. Subjects have pri-
marily been recruited through advertising on the Internet or in newspa-
pers as well as through the Danish national registry of citizens, and they
have all provided written informed consent before enrollment.
All of the healthy subjects in the database have been carefully
screened for diseases and use of pharmaceuticals and stimulants before
inclusion, and none of them have hence at the time of enrollment been
in conﬂict with any of the general exclusion criteria listed in Table 1. An
overview of the patient/case cohorts in Cimbi is provided in Table 2.
Data overview
Currently, the Cimbi database contains up to 2000 different variables
for each single person. The current variables are grouped into the fol-
lowing categorieswhich are described inmuchmore detail in a compre-
hensive document “Cimbi Instruments” which can be made available
upon mail request at cimbi(a)cimbi.dk.
• Somatic, neurological and physical measures
• Biochemical measures
○ Genetic polymorphisms relevant for the 5-HT system
○ Cortisol awakening response
○ Plasma amino acids (tryptophan) and sex steroid hormones
○ General blood screening
• Self-reported questionnaire battery
○ Questionnaires describing mental and physical state
■ Physical Activity Level
■ Major Depression Inventory
■ Proﬁle of Mood States
■ Cohen's Perceived Stress
■ The Pittsburgh Sleep Quality Index
■ Revised Hopkins Symptom Check List
○ Questionnaires describing personality traits
■ Buss–Perry Aggression Questionnaire
■ Barratt's Impulsiveness Scale
■ Highly Sensitive Person Scale
■ Sensation Seeking Scale
■ Temperament and Character Inventory
■ The NEO Personality Inventory Revised
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family predisposition to neuropsychiatric diseases, use of stimu-
lants, and education
■ Edinburgh Handedness Inventory
■ Stimulants, Education and Family History Assessment Module
■ Parental Bonding Instrument
■ Positive Life Events
■ Stressful Life Events• Neuropsychological measures based on 11 paper/computer tests
for memory, attention, language abilities and word ﬂuency, vi-
suospatial speed, executive functioning, and logic reasoning
• PET data, including basic scan information, quantiﬁed binding
potentials, and pointers to image ﬁles, from the following list of
targets and radiotracers:
○ 5-HTT with [11C]DASB
○ 5-HT1A receptor with [11C]CUMI-101
○ 5-HT1B receptor with [11C]AZ10419369
○ 5-HT2A receptor with [18F]Altanserin (antagonist) or
[11C]Cimbi-36 (agonist)
○ 5-HT4 receptor with [11C]SB207145
○ Amyloid beta peptide with [11C]PiB
○ GABAA receptors with [11C]ﬂumazenil
• MRI data, including basic scan information and pointers to image
ﬁles, based on standardized acquisition protocols containing:
○ Structural/anatomical scans:
■ A high-resolution 3D T1-weighted, sagittal, magnetization
prepared rapid gradient echo (MPRAGE) scan of the head
■ A high-resolution 3D T2-weighted, sagittal, Turbo Spin Echo
(TSE) scan of the head
■ A diffusion-weighted (DW) whole brain scan using a twice-
refocused balanced spin echo sequence that minimizes eddy
current distortion (Reese et al., 2003)
■ A gradient echo based B0 ﬁeld map sequence
○ Functional (fMRI) scans:
■ Resting-state fMRI
■ Activation fMRI using several paradigms, including an emo-
tional faces task, a gambling task, and a point subtraction ag-
gression paradigm.Neuroimaging data
Cohort
Out of the total number of subjects in the database, currently 402
healthy individuals and 206 patients have been PET and MRI scanned.
Many of these have multiple time points either under placebo, i.e.
baseline + rescan, or active intervention, i.e. baseline + intervention
rescan. Employed interventions include placebo-controlled studies
with SSRI (n = 24), acute tryptophan depletion (n = 22), bright light
intervention (n = 16), ovarian hormone manipulation (n = 31), and
bariatric surgery (n = 23). Also, in the PET/MRI scanned cohort there
are approximately 100 healthy individuals and 100 patients/cases
with scans for multiple receptors, e.g. 5-HTT/5-HT2A or 5-HTT/5-HT4,
which provides an unprecedented opportunity to study covariance of
receptor types. In total, the database currently comprises nearly 1100
PET and 1000 MRI scans.MRI data acquisition and processing
Until 2013, all Cimbi subjects were MRI scanned at the Danish Re-
search Centre for Magnetic Resonance, Copenhagen University Hospital
Hvidovre, Denmark, in a 3 T SiemensMagnetom Trio with an 8-channel
head coil (n = 775), or a 3 T Siemens Magnetom Verio scanner with a32-channel head coil (n = 127). Since 2013 all Cimbi subjects have
been MRI scanned at Copenhagen University Hospital, Rigshospitalet,
Denmark, in a 3 T Siemens Magnetom Verio with a 32-channel head
coil (n = 34), a 3 T Siemens Prisma with a 64-channel head coil (n =
50), or a 3 T Siemens Biograph (combined PET/MRI) with a 12-
channel head coil (n = 15).
Both T1- and T2-weighted images have been corrected for spatial
distortions due to non-linearity in the gradient system of the scanner
(Jovicich et al., 2006) using the Gradient Non-Linearity Distortion Cor-
rection software distributed by the Biomedical Informatics Research
Network (http://www.nbirn.net). Resulting MRI images are referred
to as ‘raw’ T1- and T2-weighted images. The ‘raw’ T1-weighted MRIs
have been segmented into graymatter, white matter and cerebrospinal
ﬂuid using Statistical Parametric Mapping software (SPM; Wellcome
Department of Cognitive Neurology, London, UK, http://www.ﬁl.ion.
ucl.ac.uk/spm/software/) and the ‘raw’ T2-weighted MRIs applied for
brain-masking purposes. For the DW images, fractional anisotropy
(FA), mean diffusivity (MD) as well as diffusivity parallel and perpen-
dicular to the principal diffusion direction have been extracted as the
ﬁnal DW outcome to be stored in the database. Processing of fMRI im-
ages has been performed using SPM software, and for the statistical
analysis a block design has been implemented for the emotional faces
paradigm, amixed block and event-related design for the point subtrac-
tion aggression paradigm, and an event-related design for the other par-
adigms. To ensure a high quality of the Cimbi MRI data, the processing
stream has been standardized and all MRI scans have been visually
inspected by an experienced researcher. Images with interfering arti-
facts have been excluded.
PET data acquisition and reconstruction
As illustrated in Fig. 3, all PET data in Cimbi have been acquired at
Rigshospitalet using one of two scanners: (1) a clinical 18-ring GE-
Advance scanner operating in 3D-acquisition mode with an approxi-
mate in-plane resolution of 6 mm (n = 387) or (2) a Siemens ECAT
HRRT (High Resolution Research Tomograph) scanner operating in
3D-acquisition mode with an approximate in-plane resolution of less
than 2 mm (n = 709). The former is no longer in function.
Whereas all GE-Advance scans have been reconstructed using ﬁl-
tered back projection and corrected for attenuation, dead-time, and
scatter, all PET images acquired on the HRRT scanner have been recon-
structed using a 3D-OSEM-PSF (Comtat et al., 2008; Hong et al., 2007;
Sureau et al., 2008) with a point spread function (PSF) of 4 mm.
Combined PET and MRI analysis
For all dynamic PET-images single-subject inter-frame motion cor-
rection has been performed using the AIR algorithm (Woods et al.,
1992). PET and MRI from the same individual have been coregistered
automatically using the AIR algorithm for the GE-Advance scans and
SPM software for the HRRT scans and conﬁrmed by visual inspection
in all planes. On each individual's MRI a set of 17 predeﬁned brain re-
gions (left and right) of interest has been automatically delineated in a
user-independent fashion with the Pvelab software package (Svarer
et al., 2005) enabling region-based PET analysis. For the dynamic PET
images, time–activity curves (TACs) reﬂecting the mean of gray-
matter voxels within each PET region have been determined and kinetic
modeling of regional TACs performed with the PMOD software (PMOD
Technologies, Zurich, Switzerland) using simpliﬁed ormultilinear refer-
ence tissuemodels (SRTM,MRTM, orMRTM2)with cerebellum as a ref-
erence region. For the steady state PET images, instead acquired blood
input values have been used in the quantiﬁcation. Eventually, regional
binding potential values, BPND or BPP depending on the radiotracer,
have been extracted as the ﬁnal PET outcome to be stored in the data-
base. Parametric binding potential maps have also been created with
the PMOD software for several of the PET images as well as with a
FreeSurfer-based approach (Greve et al., 2014).
Fig. 3. Distribution of the different types of PET scans acquired on the GE-Advance and HRRT scanners, respectively.
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tions have been taken with regard to how data are processed. First, the
processing procedure including quality control routines has been strict-
ly standardized and well-documented. Secondly, all new researchers
have received thorough and supervised in-house training on existing
datasets before being certiﬁed to analyze new data. Last but not least,
general stability in the processing results over time and across projects
has occasionally been conﬁrmed by ensuring that the regional binding
potentials have not drifted over time.The Cimbi biobank
The Cimbi biobank currently contains samples from around 500
healthy controls and 300 patients. In line with the expected increase
of subjects enrolled in the database, we also expect the number of
biobank samples to increase by 50 to 100 new sets per year. In total,
the biobank currently contains approximately 8000 blood samples
(serum, plasma, whole blood and buffy coat), 3500 saliva samples,
and puriﬁed DNA ready for genotyping. Since 2011 we have systemati-
cally collected peripheral blood for RNA extraction which allows for a
stabilized snapshot of the gene expression proﬁle at the time of blood
collection.Cimbi database
Technically, the database has been implemented in SAS® and is
stored securely at the IT system of Rigshospitalet. In accordance with
the Danish Act on Processing of Personal Data access to the database is
strictly controlled and logged, and all data are automatically backed-up.
Several steps have been implemented to ensure high quality of the
registration of data in the database. First of all, automatic data import
has been utilized whenever feasible to minimize the risk of incorrect
manual data entry. Secondly, the number of individuals with manual
data entry rights has beenkept at aminimum. Thirdly, automatic valida-
tion rules have been implemented whenever possible to ensure only
valid formats and value ranges onmanually registered data, and fourth-
ly, processed data are not imported into the database before being
reproduced and validated by an independent person. Together with
the manual quality control implemented in the actual acquisition and
processing of data, as described previously, these four steps help to
eliminate the vast majority of potential errors. However, inevitably
from time to time there are a few errors which escape the quality con-
trol, and when such errors are encountered data are corrected and re-
searchers that are affected by the errors notiﬁed.Getting access to data
Researchers who wish to get access to Cimbi data must complete a
standardized database application form (downloadable at http://
www.cimbi.dk/db) to provide detailed information about the speciﬁc
database request, i.e. background, hypothesis, aims, requested vari-
ables/ﬁles, time schedule, expected scientiﬁc outcome, and potential
contribution to the database. The application will then be reviewed by
the Cimbi Council of Investigators (CoI) group and handled by the
Cimbi Center Manager. This procedure ensures the required level of sci-
entiﬁc excellence and that relevant collaborators from Cimbi who have
collected or analyzed the requested data are duly credited in publica-
tions that arise from the research, either through a co-authorship or
an acknowledgment. Also, it ensures that a proper data support struc-
ture is in place and that data are exploited better and within a shorter
time frame. If data are not analyzed and published within the indicated
time schedule, the Cimbi CoI group may decide to grant the data to an-
other scientist capable of exploiting the data. Finally, this procedure pro-
vides a system for updating users if data are revised or withdrawn as it
creates a neat overview of the data ﬂow from the database.
Various output formats are available for a given granted database ex-
traction, including Excel (.xlsx), SAS (.sas7bdat and .sd2) and standard
text (.csv, .txt, .tab) formats. In many cases, a citable paper reference rel-
evant for the extracted data can be provided aswell. If requested, recon-
structed PET images, ‘raw’MRI images (corrected for spatial distortions
but not segmented), and raw as well as pre-processed fMRI images can
be made available in compressed ANALYZE or NIFTI format through the
department's local ﬁle sharing system, which can handle large data
transfers.
Our current database approval from the Danish Data Protection
Agency enables immediate sharing of coded data with collaborating
partners within the European Union (EU) and anonymized data with
collaborating partners outside of EU. If a given data request necessitates
sharing of personally identiﬁable information, then this ﬁrst requires a
case-speciﬁc approval from the Danish Data Protection Agency. We
have previously been successful in obtaining such an approval.Long term plans for the database
As new participants will still be enrolled in ongoing and future pro-
jects, the number of subjects in thedatabasewill continuously grow.We
expect the number to increase by approximately 50 to 100 new subjects
per year. Since future projects might involve new categories of data and
since successful completion of data requests might result in new data
enriching the database, the database is also dynamic in the total number
1218 G.M. Knudsen et al. / NeuroImage 124 (2016) 1213–1219of variables. The plan is to seek funding to continue the management
and maintenance of the database.
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